Elvitegravir 150 mg and 85 mg tablets.
Elvitegravir (tradename Vitekta) is an integrase inhibitor that needs to be boosted to reach effective drug levels.
Elvitegravir was approved in Europe in November 2013 to be used in combinations that include a ritonavir-boosted protease inhibitor.
- 85 mg tablet is for use in combinations that include atazanavir/ritonavir 300 mg/100 mg or the combined lopinavir/ritonavir 400 mg.
- 150 mg tablet is for use with the ritonavir-boosted protease inhibitors darunavir 600 mg and fosamprenavir 700 mg.
- Elvitegravir needs to be taken with food. The amount of type of food is not included in this recommendation but it may be important to include fat. The food interaction study reported that elvitegravir exposure (total drug levels over the dose period, called the AUC) increased by 36% with a light meal (~373 kcal, 20% fat) and by 91% with a high-fat meal (~800 kcal, 50% fat).
- Drug interactions include with antacid medicines which can reduce levels of elvitegravir. Antacids need to be separated by at least four hours.
- A potential interaction means that multivitamins and elvitegravir need to be separated by at least four hours.
Elvitegravir has the trade name Vitekta.
Elvitegravir is included in this fixed dose combination tablet Stribild.
The European patient information and detailed Product Information for atazanavir are available in PDF format from this link on the European Medicines Agency (EMA) website.
The Patient Information is a simplified summary: what the drug is, why it is used, results from studies and cautions including side effects.
The Product Information is a detailed technical summary that you can access as a PDF file by clicking the ‘Product Information’ tab. It describes more precisely how the drug works and how it is processed by your body. This includes, for example, reported food interaction studies in terms of calories or fat content. It includes more details of the study results and a full list of side effects and drug interactions.
Link to information about elvitegravir on the EMA website.